// App-Quantinova.ai

: A sequential therapy with sorafenib followed by regorafenib against single-line atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC): Indirect treatment comparisons (ITC) using the RESORCE study.

Researchers

Presenter

  • Jamie Partridge

Principal Investigators

  • David Aceituno

  • Noman Paracha

  • Howard Thom

Medical Centers

  • Pontificia Universidad Catolica de Chile, Santiago, Chile

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • Teva Pharmaceuticals Basel Switzerland

  • Clifton Insight, Bristol, United Kingdom

Locations

  • Switzerland

  • Chile

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Atezolizumab

  • Bevacizumab

  • Regorafenib

  • Sorafenib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved